Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
American Journal of Clinical Dermatology
Published in: American Journal of Clinical Dermatology 2/2022

01-03-2022 | Contraception | Therapy in Practice

Treating Acne in Transgender Persons Receiving Testosterone: A Practical Guide

Authors: Rakan Radi, Sarah Gold, Juan P. Acosta, Jason Barron, Howa Yeung

Published in: American Journal of Clinical Dermatology | Issue 2/2022

Login to get access

Abstract

Transgender persons who undergo masculinizing hormone therapy experience a wide array of dermatologic effects as they initiate and maintain testosterone therapy. Acne is one of the most common adverse effects for many transmasculine patients receiving testosterone. Acne can worsen body image and mental health, with significant impact on quality of life in transgender patients. Specific training and awareness are needed for a clinically and culturally competent encounter while providing care for the transgender patient. This article provides a practical guide for the treatment of testosterone-induced acne in transmasculine patients. Recommendations on creating a welcoming clinical setting, taking a gender-inclusive history, and conducting a patient-centered physical examination relevant to acne care are provided. Assessment of reproductive potential and the appropriate contraceptive methods before prescribing acne treatment with teratogenic potential in transmasculine patients are examined. Interactions between acne treatments with gender-affirming therapies are explored. For patients with severe or treatment-refractory acne, indications, contraindications, and barriers to isotretinoin prescription, such as the US iPLEDGE program, are examined. Multidisciplinary approaches to acne care, involving mental health, reproductive health, gender-affirming hormone therapy and surgeries, are adopted to guide isotretinoin treatment.
Literature
1.
Tan JK, Bhate K. A global perspective on the epidemiology of acne. Br J Dermatol. 2015;172(Suppl 1):3–12.PubMedCrossRef
2.
Karimkhani C, Dellavalle RP, Coffeng LE, Flohr C, Hay RJ, Langan SM, et al. Global skin disease morbidity and mortality: an update from the global burden of disease study 2013. JAMA Dermatol. 2017;153(5):406–12.PubMedPubMedCentralCrossRef
3.
4.
5.
6.
Melnik B, Jansen T, Grabbe S. Abuse of anabolic-androgenic steroids and bodybuilding acne: an underestimated health problem. J Dtsch Dermatol Ges. 2007;5(2):110–7.PubMedCrossRef
7.
Ragmanauskaite L, Kahn B, Ly B, Yeung H. Acne and the lesbian, gay, bisexual, or transgender teenager. Dermatol Clin. 2020;38(2):219–26.PubMedCrossRef
8.
Motosko CC, Zakhem GA, Pomeranz MK, Hazen A. Acne: a side-effect of masculinizing hormonal therapy in transgender patients. Br J Dermatol. 2019;180(1):26–30.PubMedCrossRef
9.
10.
Davis SR, Braunstein GD. Efficacy and safety of testosterone in the management of hypoactive sexual desire disorder in postmenopausal women. J Sex Med. 2012;9(4):1134–48.PubMedCrossRef
11.
Yeung H, Luk KM, Chen SC, Ginsberg BA, Katz KA. Dermatologic care for lesbian, gay, bisexual, and transgender persons: terminology, demographics, health disparities, and approaches to care. J Am Acad Dermatol. 2019;80(3):581–9.PubMedPubMedCentralCrossRef
12.
Coleman E, Bockting W, Botzer M, Cohen-Kettenis P, DeCuypere G, Feldman J, et al. Standards of care for the health of transsexual, transgender, and gender-nonconforming people, version 7. Int J Transgend. 2012:165–232.
13.
Thoreson N, Park JA, Grasso C, Potter J, King DS, Marc LG, et al. Incidence and factors associated with acne among transgender patients receiving masculinizing hormone therapy. JAMA Dermatol. 2021;157(3):290–5.PubMedCrossRef
14.
Wierckx K, Van de Peer F, Verhaeghe E, Dedecker D, Van Caenegem E, Toye K, et al. Short- and long-term clinical skin effects of testosterone treatment in trans men. J Sex Med. 2014;11(1):222–9.PubMedCrossRef
15.
Park JA, Carter EE, Larson AR. Risk factors for acne development in the first 2 years after initiating masculinizing testosterone therapy among transgender men. J Am Acad Dermatol. 2019;81(2):617–8.PubMedCrossRef
16.
Nakamura A, Watanabe M, Sugimoto M, Sako T, Mahmood S, Kaku H, et al. Dose-response analysis of testosterone replacement therapy in patients with female to male gender identity disorder. Endocr J. 2013;60(3):275–81.PubMedCrossRef
17.
Yeung H, Ragmanauskaite L, Zhang Q, Kim J, Tangpricha V, Getahun D, et al. Prevalence of moderate to severe acne in transgender adults: a cross-sectional survey. J Am Acad Dermatol. 2020;83(5):1450–2.PubMedPubMedCentralCrossRef
18.
Peitzmeier SM, Silberholz J, Gardner IH, Weinand J, Acevedo K. Time to first onset of chest binding-related symptoms in transgender youth. Pediatrics. 2021;147(3):e20200728.PubMedCrossRef
19.
Becerra-Culqui TA, Liu Y, Nash R, Cromwell L, Flanders WD, Getahun D, et al. Mental health of transgender and gender nonconforming youth compared with their peers. Pediatrics. 2018;141(5):e20173845.PubMedCrossRef
20.
Rowniak S, Bolt L, Sharifi C. Effect of cross-sex hormones on the quality of life, depression and anxiety of transgender individuals: a quantitative systematic review. JBI Database Syst Rev Implement Rep. 2019;17(9):1826–54.CrossRef
21.
Dunn LK, O’Neill JL, Feldman SR. Acne in adolescents: quality of life, self-esteem, mood, and psychological disorders. Dermatol Online J. 2011;17(1):1.PubMedCrossRef
22.
Owen-Smith AA, Gerth J, Sineath RC, Barzilay J, Becerra-Culqui TA, Getahun D, et al. Association between gender confirmation treatments and perceived gender congruence, body image satisfaction, and mental health in a cohort of transgender individuals. J Sex Med. 2018;15(4):591–600.PubMedPubMedCentralCrossRef
23.
Covelli I, Ahrens K, Onchiri FM, Inwards-Breland D, Boos MD. Influence of gender and sexual identity on adolescent skin health. Pediatr Dermatol. 2021;38(Suppl 2):65–72.PubMedCrossRef
24.
Braun H, Zhang Q, Getahun D, Silverberg MJ, Tangpricha V, Goodman M, et al. Moderate-to-severe acne and mental health symptoms in transmasculine persons who have received testosterone. JAMA Dermatol. 2021;157(3):344–6.PubMedPubMedCentralCrossRef
25.
Kcomt L, Gorey KM, Barrett BJ, McCabe SE. Healthcare avoidance due to anticipated discrimination among transgender people: a call to create trans-affirmative environments. SSM Popul Health. 2020;11:100608.PubMedPubMedCentralCrossRef
26.
Safer JD, Coleman E, Feldman J, Garofalo R, Hembree W, Radix A, et al. Barriers to healthcare for transgender individuals. Curr Opin Endocrinol Diabetes Obes. 2016;23(2):168–71.PubMedPubMedCentralCrossRef
27.
Rafferty J, Committee On Psychosocial Aspects of Child and Family Health, Committee On Adolescence, Section On Lesbian Gay, Bisexual, and Transgender Health and Wellness. Ensuring comprehensive care and support for transgender and gender-diverse children and adolescents. Pediatrics. 2018;142(4):e20182162.PubMedCrossRef
28.
Yeung H, Luk KM, Chen SC, Ginsberg BA, Katz KA. Dermatologic care for lesbian, gay, bisexual, and transgender persons: epidemiology, screening, and disease prevention. J Am Acad Dermatol. 2019;80(3):591–602.PubMedPubMedCentralCrossRef
29.
30.
Haider A, Adler RR, Schneider E, Uribe Leitz T, Ranjit A, Ta C, et al. Assessment of patient-centered approaches to collect sexual orientation and gender identity information in the emergency department: the EQUALITY study. JAMA Netw Open. 2018;1(8):e186506.PubMedPubMedCentralCrossRef
31.
Mansh MD, Nguyen A, Katz KA. Improving dermatologic care for sexual and gender minority patients through routine sexual orientation and gender identity data collection. JAMA Dermatol. 2019;155(2):145–6.PubMedCrossRef
32.
Hashemi L, Weinreb J, Weimer AK, Weiss RL. Transgender care in the primary care setting: a review of guidelines and literature. Fed Pract. 2018;35(7):30–7.PubMedPubMedCentral
33.
Krempasky C, Harris M, Abern L, Grimstad F. Contraception across the transmasculine spectrum. Am J Obstet Gynecol. 2020;222(2):134–43.PubMedCrossRef
34.
35.
Marks DH, Awosika O, Rengifo-Pardo M, Ehrlich A. Dermatologic surgical care for transgender individuals. Dermatol Surg. 2019;45(3):446–57.PubMedCrossRef
36.
Light AD, Obedin-Maliver J, Sevelius JM, Kerns JL. Transgender men who experienced pregnancy after female-to-male gender transitioning. Obstet Gynecol. 2014;124(6):1120–7.PubMedCrossRef
37.
Yeung H, Chen SC, Katz KA, Stoff BK. Prescribing isotretinoin in the United States for transgender individuals: ethical considerations. J Am Acad Dermatol. 2016;75(3):648–51.PubMedCrossRef
38.
Zaenglein AL, Pathy AL, Schlosser BJ, Alikhan A, Baldwin HE, Berson DS, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945-73.e33.CrossRef
39.
Tan J, Thiboutot D, Popp G, Gooderham M, Lynde C, Del Rosso J, et al. Randomized phase 3 evaluation of trifarotene 50 μg/g cream treatment of moderate facial and truncal acne. J Am Acad Dermatol. 2019;80(6):1691–9.PubMedCrossRef
40.
Chien AL, Qi J, Rainer B, Sachs DL, Helfrich YR. Treatment of acne in pregnancy. J Am Board Fam Med. 2016;29(2):254–62.PubMedCrossRef
41.
42.
Gamble R, Dunn J, Dawson A, Petersen B, McLaughlin L, Small A, et al. Topical antimicrobial treatment of acne vulgaris: an evidence-based review. Am J Clin Dermatol. 2012;13(3):141–52.PubMedCrossRef
43.
Rosette C, Agan FJ, Mazzetti A, Moro L, Gerloni M. Cortexolone 17α-propionate (clascoterone) is a novel androgen receptor antagonist that inhibits production of lipids and inflammatory cytokines from sebocytes in vitro. J Drugs Dermatol. 2019;18(5):412–8.PubMed
44.
Hebert A, Thiboutot D, Stein Gold L, Cartwright M, Gerloni M, Fragasso E, et al. Efficacy and safety of topical clascoterone cream, 1%, for treatment in patients with facial acne: two phase 3 randomized clinical trials. JAMA Dermatol. 2020;156(6):621–30.PubMedCrossRef
45.
DeGrazia TM, Rolader R, Thiboutot DM, Yeung H. Eligibility criteria related to hormone therapy in acne clinical trials: a systematic review. J Invest Dermatol. 2021;141(1):189–91.PubMedCrossRef
46.
Marks DH, Mansh MD. Potential role for topical antiandrogens in the management of acne among patients receiving masculinizing hormone therapy. JAMA Dermatol. 2020;156(12):1380–1.PubMedCrossRef
47.
Webster GF, Graber EM. Antibiotic treatment for acne vulgaris. Semin Cutan Med Surg. 2008;27(3):183–7.PubMedCrossRef
48.
49.
Garner SE, Eady A, Bennett C, Newton JN, Thomas K, Popescu CM. Minocycline for acne vulgaris: efficacy and safety. Cochrane Database Syst Rev. 2012;2012(8):CD002086.PubMedCentral
50.
Cross R, Ling C, Day NP, McGready R, Paris DH. Revisiting doxycycline in pregnancy and early childhood–time to rebuild its reputation? Expert Opin Drug Saf. 2016;15(3):367–82.PubMedPubMedCentralCrossRef
51.
Farrah G, Tan E. The use of oral antibiotics in treating acne vulgaris: a new approach. Dermatol Ther. 2016;29(5):377–84.PubMedCrossRef
52.
Garthwaite SM, McMahon EG. The evolution of aldosterone antagonists. Mol Cell Endocrinol. 2004;217(1–2):27–31.PubMedCrossRef
53.
Grandhi R, Alikhan A. Spironolactone for the treatment of acne: a 4-year retrospective study. Dermatology. 2017;233(2–3):141–4.PubMedCrossRef
54.
Oge LK, Broussard A, Marshall MD. Acne vulgaris: diagnosis and treatment. Am Fam Physician. 2019;100(8):475–84.PubMed
55.
Giltay EJ, Gooren LJ. Effects of sex steroid deprivation/administration on hair growth and skin sebum production in transsexual males and females. J Clin Endocrinol Metab. 2000;85(8):2913–21.PubMedCrossRef
56.
Layton AM, Eady EA, Whitehouse H, Del Rosso JQ, Fedorowicz Z, van Zuuren EJ. Oral spironolactone for acne vulgaris in adult females: a hybrid systematic review. Am J Clin Dermatol. 2017;18(2):169–91.PubMedPubMedCentralCrossRef
57.
58.
59.
Barbieri JS, Spaccarelli N, Margolis DJ, James WD. Approaches to limit systemic antibiotic use in acne: systemic alternatives, emerging topical therapies, dietary modification, and laser and light-based treatments. J Am Acad Dermatol. 2019;80(2):538–49.PubMedCrossRef
60.
Gollnick H, Cunliffe W, Berson D, Dreno B, Finlay A, Leyden JJ, et al. Management of acne: a report from a global alliance to improve outcomes in acne. J Am Acad Dermatol. 2003;49(1 Suppl):S1-37.PubMedCrossRef
61.
Strauss JS, Leyden JJ, Lucky AW, Lookingbill DP, Drake LA, Hanifin JM, et al. A randomized trial of the efficacy of a new micronized formulation versus a standard formulation of isotretinoin in patients with severe recalcitrant nodular acne. J Am Acad Dermatol. 2001;45(2):187–95.PubMedCrossRef
62.
Turrion-Merino L, Urech-Garcia-de-la-Vega M, Miguel-Gomez L, Harto-Castano A, Jaen-Olasolo P. Severe acne in female-to-male transgender patients. JAMA Dermatol. 2015;151(11):1260–1.PubMedCrossRef
63.
64.
Katz KA. Transgender patients, isotretinoin, and US Food and Drug Administration-mandated risk evaluation and mitigation strategies: a prescription for inclusion. JAMA Dermatol. 2016;152(5):513–4.PubMedCrossRef
65.
66.
67.
Kane S, Admani S. COVID-19 pandemic leading to the accelerated development of a virtual health model for isotretinoin. J Dermatol Nurses Assoc. 2021;13(1):54–7.PubMedCrossRef
68.
Marqueling AL, Zane LT. Depression and suicidal behavior in acne patients treated with isotretinoin: a systematic review. Semin Cutan Med Surg. 2005;24(2):92–102.PubMedCrossRef
69.
Huang YC, Cheng YC. Isotretinoin treatment for acne and risk of depression: a systematic review and meta-analysis. J Am Acad Dermatol. 2017;76(6):1068-76 e9.PubMedCrossRef
70.
Johnson B, Leibowitz S, Chavez A, Herbert SE. Risk versus resiliency: addressing depression in lesbian, gay, bisexual, and transgender youth. Child Adolesc Psychiatr Clin N Am. 2019;28(3):509–21.PubMedCrossRef
71.
Budge SL, Adelson JL, Howard KA. Anxiety and depression in transgender individuals: the roles of transition status, loss, social support, and coping. J Consult Clin Psychol. 2013;81(3):545–57.PubMedCrossRef
72.
Campos-Munoz L, Lopez-De Lara D, Conde-Taboada A, Fueyo Casado A, Lopez-Bran E. Depression in transgender adolescents under treatment with isotretinoin. Clin Exp Dermatol. 2020;45(5):615–6.PubMedCrossRef
73.
Peng T, Li ZM, Liu J, Zhang Y. Evaluation of reliability and validity of the Patient Health Questionnaire-9 in patients with acne. Dermatol Ther. 2020;33(4):e13584.PubMedCrossRef
74.
Singer S, Keuroghlian AS. A call for gender identity data collection in iPLEDGE and increasing the number of isotretinoin prescribers among transgender health providers. LGBT Health. 2020;7(5):216–9.PubMedCrossRef
Metadata
Title
Treating Acne in Transgender Persons Receiving Testosterone: A Practical Guide
Authors
Rakan Radi
Sarah Gold
Juan P. Acosta
Jason Barron
Howa Yeung
Publication date
01-03-2022
Publisher
Springer International Publishing
Published in
American Journal of Clinical Dermatology / Issue 2/2022
Print ISSN: 1175-0561
Electronic ISSN: 1179-1888
DOI
https://doi.org/10.1007/s40257-021-00665-w

Other articles of this Issue 2/2022

American Journal of Clinical Dermatology 2/2022 Go to the issue

Original Research Article

Culprit Medications and Risk Factors Associated with Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Population-Based Nested Case–Control Study

Review Article

Photoprotection for Skin of Color

Review Article

Medical Management of Hidradenitis Suppurativa with Non-Biologic Therapy: What’s New?

Therapy in Practice

Pruritus in Pregnancy

Leading Article

New Developments in Topical Acne Therapy

Review Article

Leukonychia: What Can White Nails Tell Us?